Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 9/20 | 0.62 |
| ▸ | KDR | P35968 | 8/20 | 0.62 |
| ▸ | JAK2 | O60674 | 2/20 | 0.62 |
| ▸ | RET | P07949 | 2/20 | 0.62 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.62 |
| ▸ | CDK1 | P06493 | 2/20 | 0.62 |
| ▸ | ROS1 | P08922 | 2/20 | 0.62 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.62 |
| ▸ | CDK2 | P24941 | 2/20 | 0.62 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.62 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.62 |
| ▸ | CLK2 | P49760 | 2/20 | 0.62 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.62 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.62 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.62 |
| ▸ | CDC7 | O00311 | 1/20 | 0.62 |
| ▸ | PLK4 | O00444 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13860277 | 1.00 | SRC (0.62) | SRCKDRJAK2RETDYRK3 | |
| Hydrochloric Acid SCHEMBL17911530 | 0.99 | SRC (0.60) | SRCKDRJAK2RETDYRK3 | |
| Hydrochloric Acid SCHEMBL4824866 | 0.99 | SRC (0.60) | SRCKDRJAK2RETDYRK3 | |
| Hydrochloric Acid SCHEMBL17770592 | 0.99 | SRC (0.60) | SRCKDRJAK2RETDYRK3 | |
| SCHEMBL24251864 | 0.92 | SRC (0.64) | SRCKDRJAK2RETDYRK3 | |
| SCHEMBL4821519 | 0.92 | SRC (0.64) | SRCKDRJAK2RETDYRK3 | |
| SCHEMBL14693624 | 0.92 | SRC (0.64) | SRCKDRJAK2RETDYRK3 | |
| Acetic Acid SCHEMBL4821413 | 0.92 | RET (0.57) | SRCKDRJAK2RETDYRK3 | |
| Acetic Acid SCHEMBL4821418 | 0.92 | RET (0.57) | SRCKDRJAK2RETDYRK3 | |
| Hydrochloric Acid SCHEMBL4826416 | 0.91 | SRC (0.63) | SRCKDRJAK2RETDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246327-B1 | 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF | SI CHUAN UNIV (CN) | 2022-11-23 | — | — | EP | disclosed |
| EP-3138842-B1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | ZHEJIANG DTRM BIOPHARMA CO LTD (CN) | 2020-12-09 | — | — | EP | disclosed |
| EP-3138842-B1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | ZHEJIANG DTRM BIOPHARMA CO LTD (CN) | 2020-12-09 | — | — | EP | disclosed |
| CN-108295073-B | Polyfluoro compounds as bruton's tyrosine kinase inhibitors | 浙江导明医药科技有限公司 | 2020-06-16 | — | — | CN | disclosed |
| CN-107344940-B | BTK inhibitors and uses thereof | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10266537-B2 | 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof | St. Chuan University (CN) | 2019-04-23 | — | — | US | disclosed |
| US-10266537-B2 | 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof | St. Chuan University (CN) | 2019-04-23 | — | — | US | disclosed |
| US-20180207161-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2018-07-26 | — | — | US | disclosed |
| WO-2015165279-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | 浙江导明医药科技有限公司 | 2015-11-05 | — | — | WO | disclosed |
| EP-2710005-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012158764-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | SRC 2167/4885KDR 836/4885JAK2 1515/4885 |
| US-10266537-B2 | 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof | DPYD, TYMP, WEE1 | SRC 1111/4885KDR 2340/4885JAK2 307/4885 |
| US-20180207161-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | SRC 16/4885KDR 674/4885JAK2 17/4885 |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | BTK, LCK, LYN | SRC 16/4885KDR 674/4885JAK2 17/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | SRC 1834/4885KDR 1166/4885JAK2 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.